Примери за използване на Applicant presented на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The applicant presented literature search strategy.
Because pantoprazole has been in use for many years, the applicant presented data from the scientific literature.
The applicant presented data on experimental models from similar vaccines.
Because ciclosporin has been used for many years, the applicant presented data on experimental models from the scientific literature.
The Applicant presented the population recruited for the confirmatory study.
Хората също превеждат
Although ImmunoGam itself was not tested in experimental models, the applicant presented adequate data from studies using similar medicines.
The applicant presented in their submission the following grounds for re-examination.
Because cholic acid is a well-known substance, andits use in these enzyme deficiencies is well established, the applicant presented data from the scientific literature.
The applicant presented data on experimental models from the scientific literature.
Because mercaptamine has been used for many years to treat cystinosis andits use is well established, the applicant presented data from the medical literature to support its application for Dropcys.
The applicant presented efficacy data of Phase III study in spasmodic torticollis.
Because PecFent is a hybrid medicine, the applicant presented data on the reference medicines in addition to results from its own studies.
The applicant presented data on experimental models from the scientific literature.
Because Sancuso is a hybrid generic, the applicant presented comparative data on the reference medicine in addition to results from its own studies.
The applicant presented data from one main study involving 202 patients with PAH.
The applicant presented data on an existing nebuliser solution containing tobramycin called Tobi.
The applicant presented data from one main study involving 167 patients who underwent vascular surgery.
The applicant presented data from one main study involving 1,683 patients with osteoarthritis of the knee.
The Applicant presented hazard ratios for major cardiovascular events in Qsiva-treated subjects.
The applicant presented comparative viscosity data between the‘old' and‘new' formulations of Combimox.
The Applicant presented several literature references to justify the PK variability of pantoprazole.
The applicant presented data from two main studies in 356 anaemic patients with myelodysplastic syndromes.
The applicant presented data from two main studies involving 1073 patients with newly diagnosed multiple myeloma.
The applicant presented data on experimental models for beclomethasone dipropionate from the scientific literature.
The Applicant presented the results of a further confirmatory fed study, with a final sampling point of 30 hours.
The rationale of the applicant presented the need for the fixed dose combination in short term treatment of acute pain was presented to the CHMP.
The applicant presented a re-analysis of the data from one main study involving 1,125 patients with advanced or metastatic non-small cell lung cancer with EGFR.
The applicant presented results of a main study in 44 patients with GIST that could not be removed surgically or that had spread and was resistant to imatinib treatment.
The applicant presented data from 2 main studies involving a total of 52 children with protein C deficiency due to severe infection, where Ceprotin was compared with placebo(a dummy treatment).
The Applicant presented a pivotal and a supportive uncontrolled trial to support this indication, together with a protocol and preliminary data for another uncontrolled trial with similar design.